Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review

Nicolas Voizard, Milena Cerny, Anis Assad, Jean Sébastien Billiard, Damien Olivié, Pierre Perreault, Ania Kielar, Richard K.G. Do, Takeshi Yokoo, Claude B. Sirlin, An Tang

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


Computed tomography (CT) and magnetic resonance imaging (MRI) play critical roles for assessing treatment response of hepatocellular carcinoma (HCC) after locoregional therapy. Interpretation is challenging because posttreatment imaging findings depend on the type of treatment, magnitude of treatment response, time interval after treatment, and other factors. To help radiologists interpret and report treatment response in a clear, simple, and standardized manner, the Liver Imaging Reporting and Data System (LI-RADS) has developed a Treatment Response (LR-TR) algorithm. Introduced in 2017, the system provides criteria to categorize response of HCC to locoregional treatment (e.g., chemical ablation, energy-based ablation, transcatheter therapy, and radiation therapy). LR-TR categories include Nonevaluable, Nonviable, Equivocal, and Viable. LR-TR does not apply to patients on systemic therapies. This article reviews the LR-TR algorithm; discusses locoregional therapies for HCC, treatment concepts, and expected posttreatment findings; and illustrates LI-RADS treatment response assessment with CT and MRI.

Original languageEnglish (US)
Article number121
JournalInsights into Imaging
Issue number1
StatePublished - Dec 1 2019


  • Computed tomography
  • Hepatocellular carcinoma
  • LI-RADS Treatment Response
  • Locoregional
  • Magnetic resonance imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review'. Together they form a unique fingerprint.

Cite this